Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imaging Marker for Parkinson's Disease Using SPECT With [123I] Beta-CIT
NCT00129675Phase 2Completed
- Sponsor
- Institute for Neurodegenerative Disorders
- Start
- Feb 2003
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [123I]beta-CIT in Parkinson's disease (PD) and parkinsonian syndrome, sponsored by Institute for Neurodegenerative Disorders. Primary endpoint: Comparison of the imaging diagnosis to the clinical diagnosis at 5 years. Started Feb 2003; status: completed.
02
Drugs
[123I]beta-CIT
03
Conditions
Parkinson's disease (PD)parkinsonian syndrome
Beyond the preview
Go deeper on NCT00129675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129675.